Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be reconfigured within days during a pandemic—the drugmaker said it has opened a similar facility in Singapore.

Located in the Tuas Biomedical Park and erected with an investment of 558 million euros ($590 million), It becomes the first modular manufacturing facility on the island nation, Sanofi said.

Sanofi kicked off construction of the site in April of 2022, then calling it and its sister plant in France Evolutive Vaccine Facilities (EVFs).

“More than just a factory, (Modulus) redefines healthcare delivery with flexibility and speed, enabling us to meet the changing needs of the pipeline across multiple modalities, as well as respond with urgency to future public health challenges,” Brendan O’Callaghan, Sanofi’s VP of manufacturing and supply, said in a release.

The Singapore site will be operational by the middle of 2026 and will employ a staff of 200, including “bioprocess engineers, data analysts, quality control experts, as well as experts in artificial intelligence and bioinformatics,” O’Callaghan said this morning during a ribbon-cutting ceremony. He added that the company already employs 600 in Singapore.